Maker of infant diapers, training pants and feminine hygiene products focused on Africa, Latin America and Central Asia.
Maker of infant diapers, training pants and feminine hygiene products focused on Africa, Latin America and Central Asia.
In one line: An emerging-markets Kimberly-Clark, Africa-focused.
Moat: narrow (brand, distribution, scale). Roughly #2 share in Africa's diaper and sanitary-napkin markets, built on distribution across many emerging markets.
Headquarters: Hong Kong / Africa operations · Employees: 2,906
Size Softcare (2698.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $2.20B, the 390th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$28.28 on 18 Nov 2026.
Performance Over six months the shares gained 4.9%, against -4.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 24.8% over the last twelve months (peer median +4.3%); the operating margin is 25.2% (peer median 10.5%).
Valuation It trades at 14.4× forward earnings against a peer median of 22.2× (6th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 34.7 points above its cost of capital (11.9% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$4.42B | HK$3.55B | HK$3.22B | HK$2.50B |
| Revenue growth | — | +25% | +10% | +29% | — |
| Gross profit | n/a | HK$1.59B | HK$1.25B | HK$1.12B | HK$571M |
| EBITDA | n/a | HK$1.13B | HK$974M | HK$807M | HK$338M |
| Net income | n/a | HK$945M | HK$742M | HK$506M | HK$144M |
| Free cash flow | n/a | HK$504M | HK$598M | HK$676M | -HK$194M |
| Capital expenditure | n/a | HK$408M | HK$256M | HK$67.6M | HK$246M |
| Total debt | n/a | HK$165M | HK$18.9M | HK$754M | HK$1.33B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Softcare 2698.HK | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% |
| Hengan Int'l 1044.HK | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% |
| Kimberly-Clark KMB | $65.8B | +11% | -8% | 14% | 15.2× | 5.1% |
| Procter & Gamble PG | $395B | +20% | +4% | 24% | 24.1× | 0.5% |
| Unicharm 8113.T | $13.0B | +20% | +2% | 11% | 26.9× | 0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2698.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.5% | -2.0% | 6th highest of 21 |
| 6-month return | +4.9% | -4.7% | 9th highest of 21 |
| Distance from 52-week high | -21.2% | -26.2% | 8th highest of 21 |
| Revenue growth (TTM) | +24.8% | +4.3% | 3rd highest of 21 |
| Operating margin | 25.2% | 10.5% | 3rd highest of 21 |
| Forward P/E | 14.4× | 22.2× | 6th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | -1.8% | 6th most demanding of 17 |
| Growth delivered (Del g) | +20.9% | +2.8% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | -11.8 pp | -2.0 pp | 5th least demanding of 17 |
| ROIC minus cost of capital | +34.7 pp | +5.1 pp | 3rd highest of 20 |
| EV / EBITDA | 12.5× | 10.3× | 6th most expensive of 14 |
| Net debt / EBITDA | -2.8× | -1.8× | 3rd least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |